AC Immune (NASDAQ:ACIU – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.03, Zacks reports.
AC Immune Stock Performance
Shares of ACIU stock traded up $0.01 on Thursday, reaching $2.33. 39,816 shares of the company were exchanged, compared to its average volume of 329,218. The company has a market cap of $230.04 million, a price-to-earnings ratio of -5.07 and a beta of 1.23. AC Immune has a 1 year low of $2.19 and a 1 year high of $4.98. The business has a 50-day moving average price of $2.64 and a 200 day moving average price of $2.99.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of AC Immune in a research note on Friday, November 15th.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Stories
- Five stocks we like better than AC Immune
- How to Most Effectively Use the MarketBeat Earnings Screener
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- What is MarketRank™? How to Use it
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
- What is the Nikkei 225 index?
- Is a Bottom Finally Forming in Rocket Lab Stock?
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.
